Chemo-Pharma [CPL] vs Uniparts India [UNIPARTS] Detailed Stock Comparison
Chemo-Pharma
BSE
Loading...
Uniparts India
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Chemo-Pharma wins in 8 metrics, Uniparts India wins in 11 metrics, with 0 ties. Uniparts India appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Chemo-Pharma | Uniparts India | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 11.95 | 19.01 | Chemo-Pharma |
| Price-to-Book Ratio | 2.52 | 2.09 | Uniparts India |
| Debt-to-Equity Ratio | 44.70 | 13.52 | Uniparts India |
| PEG Ratio | 0.61 | 0.50 | Uniparts India |
| EV/EBITDA | 13.68 | 10.68 | Uniparts India |
| Profit Margin (TTM) | 11.11% | 10.00% | Chemo-Pharma |
| Operating Margin (TTM) | 9.62% | 15.07% | Uniparts India |
| EBITDA Margin (TTM) | 9.62% | 15.07% | Uniparts India |
| Return on Equity | 20.97% | 9.92% | Chemo-Pharma |
| Return on Assets (TTM) | 11.26% | 7.52% | Chemo-Pharma |
| Free Cash Flow (TTM) | $41.66M | $1.49B | Uniparts India |
| Dividend Yield | N/A | 5.64% | N/A |
| 1-Year Return | -11.43% | -16.53% | Chemo-Pharma |
| Price-to-Sales Ratio (TTM) | 1.39 | 1.90 | Chemo-Pharma |
| Enterprise Value | $4.59B | $17.00B | Uniparts India |
| EV/Revenue Ratio | 1.57 | 1.74 | Chemo-Pharma |
| Gross Profit Margin (TTM) | 29.30% | 65.60% | Uniparts India |
| Revenue per Share (TTM) | $51 | $216 | Uniparts India |
| Earnings per Share (Diluted) | $5.66 | $21.64 | Uniparts India |
| Beta (Stock Volatility) | 0.23 | 0.68 | Chemo-Pharma |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Chemo-Pharma vs Uniparts India Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Chemo-Pharma | 0.43% | -0.38% | -7.64% | -11.83% | -19.75% | -42.01% |
| Uniparts India | 0.87% | 0.43% | 7.55% | 9.89% | 28.72% | -0.71% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Chemo-Pharma | -11.43% | 282.10% | 118.96% | 724.45% | 1,217.19% | 1,217.19% |
| Uniparts India | -16.53% | 251.37% | 250.17% | 153.51% | 153.51% | 153.51% |
News Based Sentiment: Chemo-Pharma vs Uniparts India
Chemo-Pharma
News based Sentiment: NEGATIVE
The significant financial losses reported in Q1 FY26, coupled with underperformance relative to the Sensex, create a concerning picture for investors. While the diversification strategy is a positive development, it doesn't immediately offset the current challenges. The volatile stock price and fluctuating investor participation add to the uncertainty.
Uniparts India
News based Sentiment: NEUTRAL
The month was characterized by continued investor engagement and transparency efforts from Uniparts India, with the AGM as a key upcoming event. While positive, these developments don't represent a major shift in the company's overall investment story, maintaining a neutral outlook.
Performance & Financial Health Analysis: Chemo-Pharma vs Uniparts India
| Metric | CPL | UNIPARTS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹4.05B | ₹18.57B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 32,878 | 48,432 |
| 90 Day Avg. Volume | 33,955 | 116,787 |
| Last Close | ₹67.73 | ₹413.60 |
| 52 Week Range | ₹66.00 - ₹128.00 | ₹296.65 - ₹501.30 |
| % from 52W High | -47.09% | -17.49% |
| All-Time High | ₹128.00 (Jan 06, 2025) | ₹722.65 (Jul 31, 2023) |
| % from All-Time High | -47.09% | -42.77% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 0.05% |
| Quarterly Earnings Growth | 0.34% | 0.39% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.10% |
| Operating Margin (TTM) | 0.10% | 0.15% |
| Return on Equity (TTM) | 0.21% | 0.10% |
| Debt to Equity (MRQ) | 44.70 | 13.52 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹26.86 | ₹196.66 |
| Cash per Share (MRQ) | ₹1.01 | ₹61.23 |
| Operating Cash Flow (TTM) | ₹277.99M | ₹1.66B |
| Levered Free Cash Flow (TTM) | ₹313.23M | ₹880.04M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 5.64% |
| Last 12-Month Dividend | ₹0.00 | ₹22.50 |
Valuation & Enterprise Metrics Analysis: Chemo-Pharma vs Uniparts India
| Metric | CPL | UNIPARTS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 11.95 | 19.01 |
| Forward P/E | N/A | 14.91 |
| PEG Ratio | 0.61 | 0.50 |
| Price to Sales (TTM) | 1.39 | 1.90 |
| Price to Book (MRQ) | 2.52 | 2.09 |
| Market Capitalization | ||
| Market Capitalization | ₹4.05B | ₹18.57B |
| Enterprise Value | ₹4.59B | ₹17.00B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.57 | 1.74 |
| Enterprise to EBITDA | 13.68 | 10.68 |
| Risk & Other Metrics | ||
| Beta | 0.23 | 0.68 |
| Book Value per Share (MRQ) | ₹26.86 | ₹196.66 |
Financial Statements Comparison: Chemo-Pharma vs Uniparts India
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CPL | UNIPARTS |
|---|---|---|
| Revenue/Sales | ₹697.42M | ₹2.53B |
| Cost of Goods Sold | ₹493.08M | ₹964.47M |
| Gross Profit | ₹204.34M | ₹1.56B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹67.12M | ₹243.19M |
| EBITDA | ₹79.31M | ₹416.41M |
| Pre-Tax Income | ₹55.13M | ₹287.68M |
| Income Tax | ₹12.13M | ₹59.40M |
| Net Income (Profit) | ₹42.99M | ₹228.28M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CPL | UNIPARTS |
|---|---|---|
| Cash & Equivalents | ₹12.05M | ₹328.89M |
| Total Current Assets | ₹2.51B | ₹8.14B |
| Total Current Liabilities | ₹1.17B | ₹2.16B |
| Long-Term Debt | ₹109.50M | ₹263.82M |
| Total Shareholders Equity | ₹1.49B | ₹8.87B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹144.04M | ₹2.57B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CPL | UNIPARTS |
|---|---|---|
| Operating Cash Flow | N/A | ₹492.10M |
| Capital Expenditures | N/A | ₹-68.61M |
| Free Cash Flow | N/A | ₹92.68M |
| Debt Repayment | N/A | ₹-4.03M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CPL | UNIPARTS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 32,878 | 48,432 |
| Average Daily Volume (90 Day) | 33,955 | 116,787 |
| Shares Outstanding | 57.55M | 44.98M |
| Float Shares | 17.06M | 15.07M |
| % Held by Insiders | 0.70% | 0.66% |
| % Held by Institutions | 0.00% | 0.05% |
Dividend Analysis & Yield Comparison: Chemo-Pharma vs Uniparts India
| Metric | CPL | UNIPARTS |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹22.50 |
| Last 12-Month Dividend Yield | N/A | 5.64% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹16.92 |
| 3-Year Avg Dividend Yield | N/A | 1.55% |
| 3-Year Total Dividends | ₹0.00 | ₹50.75 |
| Ex-Dividend Date | N/A | Aug 14, 2025 |